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Abstract
Epithelial-mesenchymal transition (EMT) is a critical process in invasion and metastasis of cancer cells. E-cadherin to N-
cadherin switching is considered a molecular hallmark of EMT. Recently, we reported that increased CK2 activity fully
induces E-cadherin to N-cadherin switching, but the molecular mechanisms of N-cadherin upregulation are unknown.
In this study, we examined how N-cadherin is upregulated by CK2. N-cadherin promoter analysis and ChIP analysis
identiﬁed and conﬁrmed myeloid zinc ﬁnger 1 (MZF1) as an N-cadherin transcription factor. Molecular analysis showed
that MZF1 directly interacts with CK2 and is phosphorylated at serine 27. Phosphorylation stabilizes MZF1 and induces
transcription of N-cadherin. MZF1 knockdown (MKD) in N-cadherin-expressing cancer cells downregulates N-cadherin
expression and reverts the morphology from spindle and ﬁbroblast-like to a rounded, epithelial shape. In addition, we
showed that that MKD reduced the motility and invasiveness of N-cadherin-expressing cancer cells. Collectively, these
data indicate that N-cadherin upregulation in CK2-mediated E-cadherin to N-cadherin switching is dependent on
phosphorylation-mediated MZF1 stabilization. CK2 could be a good therapeutic target for the prevention of
metastasis.
Introduction
The term epithelial-mesenchymal transition (EMT)
describes a biological process during which cells lose their
epithelial characteristics and acquire properties of
mesenchymal cells through multiple biochemical chan-
ges1. The transitioned cells are characterized by a loss of
epithelial cell polarity, disassembly of cell-cell junctions,
and increased cell motility2,3. EMT occurs during many
biological processes of normal and diseased states, such as
implantation, embryogenesis, organ development, wound
healing, tissue regeneration, organ ﬁbrosis, and tumor
progression4.
E-cadherin to N-cadherin switching, which often occurs
during EMT, refers to the replacement of E-cadherin
expression with N-cadherin5–10 and is a molecular hall-
mark of EMT4. The cadherin family mediates calcium-
dependent, homotypic cell-cell adhesion and plays
important roles in the maintenance of normal tissue
architecture11,12. The classical cadherins, E-cadherin, N-
cadherin, and P-cadherin, are expressed in speciﬁc cells
and tissues, and during speciﬁc developmental stages. E-
cadherin is the major cadherin in polarized epithelial cells,
whereas N-cadherin is expressed mainly in mesenchymal
cells13. Transcriptional repression of E-cadherin is a
major molecular mechanism for the loss of E-cadherin
expression during cadherin switching14. E-cadherin tran-
scriptional repressors have been extensively studied in the
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last decade, and they include the Snail superfamily of
zinc-ﬁnger transcriptional repressors, Snail115,16 and
Snail2 (also known as Slug)17,18, the ZEB family of tran-
scription factors, ZEB1 (also known as TCF8 and δEF1)
and ZEB2 (also known as ZFXH1B and SMAD interacting
protein 1; SIP1)19,20, bHLH factors, Twist1, E47 (also
known as TCF3), and TCF4 (also known as E2-2)21,22. In
contrast to E-cadherin, little is known about the reg-
ulatory mechanisms pertaining to the upregulation of N-
cadherin23.
Protein kinase CK2 is a constitutively active, growth
factor-independent serine/threonine protein kinase with
key roles in cell cycle control, cellular differentiation,
proliferation, and regulation of apoptosis24–26. Elevated
levels of CK2 expression or activity have been reported in
many cancer types25,27–29. In addition, overexpression of
the CK2α catalytic subunit is known to induce tumor
formation28, indicating a protumorigenic role for CK2.
Recently, we reported that increased CK2 activity fully
induces E-cadherin to N-cadherin switching and CK2
activity is required for the maintenance of N-cadherin
expression30, conﬁrming the role of CK2 in EMT.
While CK2 fully induces E-cadherin to N-cadherin
switching, the molecular mechanisms for N-cadherin
upregulation during switching remain largely unknown.
Therefore, in this study, we examined how N-cadherin is
upregulated during CK2-mediated E-cadherin to N-
cadherin switching.
Results
Identiﬁcation of MZF1 as an N-cadherin transcription factor
Previously, it was reported that MZF1 regulates N-
cadherin promoter in osteoblasts31. To identify a tran-
scription factor for regulating N-cadherin expression in
cancer cells, the human N-cadherin promoter region
(−1310 to +190) was cloned into the pGL3 basic plasmid
(pNcad-1310), and serial deletion constructs were gener-
ated (Fig. 1b). The N-cadherin promoter reporter assay
was performed in mesenchymally transitioned HCE4
cells30. N-cadherin promoter activity was reduced after
deletion of the 5′ end of the promoter to position −158
(Fig. 1b). The promoter sequences of the human N-
cadherin gene were analyzed and two MZF1-binding sites
were found in pNcad-296 (Fig. 1a, b). One of the sites was
a proximal MZF1 binding site located between the −150
and −145 positions (TGGGGA, ); this site was pre-
viously reported as an important site for N-cadherin
expression in osteoblasts31, and the other site was a distal
MZF1 binding site located between positions −277 to
−272 (TCCCCA, ) in an inverted orientation. The distal
site could be the binding site for MZF1 because it was
located between positions −296 and −158 (Fig. 1a, b).
ChIP assays conﬁrmed the results from the reporter assay
showing that MZF1 speciﬁcally binds to the distal MZF1
binding site (Fig. 1c). Consistent with this result, MZF1
overexpression signiﬁcantly increased the reporter activity
of pNcad-667 but not that of pNcad-667mt or pNcad-158
(Fig. 1d).
Conﬁrmation of MZF1 as an N-cadherin transcription factor
To conﬁrm whether MZF1 is a transcription factor for
N-cadherin expression in mesenchymally transitioned
cancer cells, we generated stable MZF1 knockdown
(MKD) HCE4 cells and TE2-CK2α30 cells using short
hairpin RNA (shRNA). Because no good MZF1 antibody
(Ab) is commercially available, RT-PCR was performed to
conﬁrm MKD. We found that MZF1 expression was
knocked down by the shRNA, and MKD resulted in
downregulation of N-cadherin expression (Fig. 2a). Con-
sistent with the RNA results, N-cadherin expression was
downregulated, as shown by western blot analysis (Fig.
2b). In addition, MKD caused morphologic changes to
mesenchymally transitioned cancer cells from spindle and
ﬁbroblast-like to a rounded, epithelial shape (Fig. 2c).
MZF1 is phosphorylated by CK2
We hypothesized that CK2 might upregulate N-
cadherin expression through phosphorylation-dependent
MZF1 modulation. First, we examined whether increased
CK2 activity could affect N-cadherin promoter activity in
cancer cells. Exogenous overexpression of the CK2α cat-
alytic subunit increased CK2 activity and enhanced the
promoter activity of pNcad-667 (Fig. 3a). Then, we
examined whether CK2 could phosphorylate MZF1. Ele-
ven potential CK2 phosphorylation sites32 in MZF1 were
predicted by the KinasePhos2.033 program. All potential
phosphorylation sites were located within the ﬁrst 360
amino acids of MZF1. Two HA-tagged MZF1 fragment
expression constructs were generated and expressed.
Fragment 1 (F1) contained amino acids 1–240, and F2
contained amino acids 120–360. Protein lysates were
immunoprecipitated and processed for the in vitro kinase
assay to detect CK2-dependent phosphorylation of these
peptides. F1, but not F2, was phosphorylated (Fig. 3b, left),
suggesting that at least one CK2 phosphorylation site is
located within amino acids 1–120. As serine 27 and serine
111 were two predicted phosphorylation sites within
amino acids 1–120, these serines were replaced with
alanine by site-directed mutagenesis. Immunoprecipita-
tion followed by in vitro kinase assay showed that full-
length MZF1 27A showed no phosphorylation, indicating
that serine 27 of MZF1 is the phosphorylation site (Fig.
3b, right). Mass spectrometric analysis also showed serine
27-phosphorylation of MZF1 by CK2 (Fig. 3c). In addi-
tion, a GST pulldown assay showed that CK2α interacted
directly with MZF1 (Fig. 3d); the interaction between
exogenous MZF1 and endogenous CK2α was conﬁrmed
in 293 cells (Fig. 3e).
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Fig. 1 (See legend on next page.)
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Effect of CK2-mediated phosphorylation on MZF1
To examine the effect of CK2-mediated phosphoryla-
tion on MZF1, TE2 cells, which have low CK2 activity25,
were cotransfected with HA-MZF1 and myc-CK2α
expression vectors. The MZF1 level was elevated in the
cells (Fig. 4a, top; lane 2 vs 1) with increased CK2 activity
(Fig. 4a, bottom; lane 2 vs 1). When CK2 activity was
inhibited by tetrabromo benzotriazole (TBB) (Fig. 4a,
bottom; lane 2 vs 3), a pharmacologic CK2 inhibitor,
expression of MZF1 returned to the level of the control
Fig. 1 Identiﬁcation of MZF1 as an N-cadherin transcription factor. a Nucleotide sequences of the 5′-ﬂanking region and exon 1 of the human N-
cadherin gene31. The ATG start codon is shown in bold, italicized font and is designated as +1. The arrowheads indicate the nucleotides at which
various deletion constructs of the N-cadherin promoter were created. Putative binding sites for MZF1 are shown in red boxes. b N-cadherin promoter
activity analysis. HCE4 cells were transiently transfected with pNcad-1310 or its 5′-serial deletion constructs. Normalized luciferase activities are shown
as mean ± SD of triplicate samples and are expressed as fold-increase relative to the luciferase activity from pGL3-basic. E-box, SP1, AP4, and MZF1-
binding sites are shown. c Chromatin immunoprecipitation (ChIP) analysis of MZF1 binding to the N-cadherin promoter. HCE4 cells were transfected
with pSG5-HA (E) or pSG5-HA-MZF1 (M); chromatin was immunoprecipitated with the indicated antibodies (top). The sequences of the forward
(−400 to −419) and reverse (−219 to −200) primers for ChIP analysis are underlined and indicated with an arrow in (a). Sequences in the distal
MZF1-binding site, TCCCCA (wt), were mutated into TCTTCA (mt) by site-directed mutagenesis of pNcad-667. Cells were cotransfected with either
pSG5-HA-MZF1 and pNcad-667wt or pSG5-HA-MZF1 and pNcad-667mt; chromatin was immunoprecipitated with the indicated antibodies (bottom).
The sequences of the reverse (−21 to −40) primer for ChIP analysis are underlined and indicated with a dashed arrow in (a). The sequences of the
forward primer are present in pGL3 basic. d Effect of exogenous MZF1 on N-cadherin promoter activity. HCE4 cells were cotransfected with pGL3-
basic, pNcad-667, pNcad-667mt, or pNcad-158 plus either pSG5-HA (E) or pSG5-HA-MZF1 (M). Western blot analysis of exogenous HA-tagged MZF1
expression is shown in the inset. Normalized luciferase activities are shown as mean ± SD of triplicate samples and are shown as fold-increase or fold-
decrease relative to the activity measured in cells cotransfected with pNcad-667 and pSG5-HA
Fig. 2 MZF1 is an N-cadherin transcription factor. a Effect of MKD on gene expression using semi-quantitative RT-PCR for indicated genes; GAPDH
was used as an internal control. HCE4 (left) and TE2-CK2α (right) scrambled shRNA: C and shRNA against MZF1: M. b Western blot analyses were
performed with the indicated antibodies. β-actin was used as a loading control for total cell lysates. c Effect of shRNA-mediated MKD on morphology.
Scale bars, 50 μm
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(Fig. 4a, top; lane 3 vs 4). To conﬁrm the correlation
between the expression level of MZF1 and CK2 activity,
we used the non-phosphorylatable MZF1 S27A mutant
that could mimic MZF1 in cells with extremely low CK2
activity and the phosphomimetic MZF1 S27E that could
mimic MZF1 in cells with extremely high CK2 activity.
HCE4 cells, which have high CK2 activity25, were
transfected with MZF1 wt, MZF1 S27A, or MZF1 S27E
expression vectors. Western blot analysis showed that the
expression level of MZF1 was correlated with its phos-
phorylation status (Fig. 4b). To examine whether CK2
activity-dependent increases in MZF1 expression are due
to phosphorylation-dependent MZF1 stabilization, we
transfected HEK293 cells with MZF1 S27A or S27E and
Fig. 3 MZF1 is phosphorylated by protein kinase CK2. a Effects of increased CK2 activity on N-cadherin promoter activity. Promoter activities of
pGL3-basic or pNcad-667 were measured in HEK293 cells expressing either pCMV-myc (E) or pCMV-myc-CK2α (C). Results of western blot analysis for
the exogenous expression of myc-CK2α and in vitro kinase assays for intracellular CK2 activity are shown in the inset. GST-CS represents input GST-CS
stained with Coomassie brilliant blue. 32P-GST-CS represents phosphorylated GST-CS. Normalized luciferase activities are shown as mean ± SD for
triplicate samples and are shown as fold-increase or fold-decrease relative to the activity from cells cotransfected with pNcad-667 and pCMV-myc. b
CK2 phosphorylates MZF1 at serine 27. HEK293 cells were transfected with HA-MZF1 F1 (amino acid residues 1 to 240 of MZF1) or F2 (amino acid
residues 120–360 of MZF1) (left) or with full-length MZF1 wt or MZF1 S27A (right). Exogenously expressed MZF1 variants were immunoprecipitated
and used as substrates for in vitro kinase assays. 32P-MZF1 represents HA-tagged MZF1 phosphorylated by CK2. c Identiﬁcation of serine 27 as a CK2
phosphorylation site in MZF1 using mass spectrometry. Fragmentation spectrum (with b and y ions indicated) of a peptide spanning from amino
acid 24 to 44 showing a phosphorylated serine at position 27 in MZF1. d Interaction between MZF1 and GST-tagged CK2α in vitro. Protein lysates
isolated from HA-tagged MZF1-overexpressing HEK293 cells were mixed with human recombinant CK2 (GST-CK2α). Immunoprecipitation with a GST-
speciﬁc Ab was followed by western blot analysis using anti-HA Ab. e Interaction between exogenous MZF1 and endogenous CK2α. HEK293 cells
were transfected with Flag-MZF1, and lysates were immunoprecipitated with anti-Flag Ab (α-Flag) followed by western blot analysis using anti-CK2α
Ab. Results of western blot analysis of total cell lysates are labeled as ‘Input’
Ko et al. Oncogenesis  (2018) 7:27 Page 5 of 12
Oncogenesis
Fig. 4 Effect of CK2-mediated phosphorylation on MZF1. a CK2 activity-dependent MZF1 expression. TE2 cells were cotransfected with HA-MZF1
and myc-CK2α expression vector. These cells were subsequently treated or not with a CK2 inhibitor, TBB (20 μM), for 24 h. Western blot analysis was
performed with the indicated antibodies (top), and in vitro kinase assays were performed (bottom). b Expression of each MZF1 phospho-mutant.
HCE4 cells were transfected with MZF1 wt, MZF1 S27A, or MZF1 S27E. Cell lysates were prepared from each transfectant followed by western blot
analysis with the indicated antibodies. c MZF1 stabilization by phosphorylation. HEK293 cells transfected with S27A or S27E were treated with
cycloheximide (CHX; 20 μM) and harvested after the indicated time intervals. Lysates were prepared, and western blot analysis was performed with
anti-HA Ab. β-actin was used as a loading control. d The relative expression levels of MZF1 were plotted against treatment time with CHX. e Effect of
MZF1 wt or each phospho-mutant on N-cadherin promoter activity. Normalized luciferase activities are shown as mean ± SD of triplicate samples and
are expressed as fold-increase or fold-decrease relative to the activity from HCE4 cells cotransfected with pNcad-667 and MZF1 wt. **P < 0.01. f
Functional effect of MZF1 expression on N-cadherin transcription. TE2 cells cotransfected with myc-CK2α and empty vector (E), MZF1 wt, or MZF1
S27A. Semi-quantitative RT-PCR was performed. GAPDH was used as an internal control
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treated the cells with cycloheximide. Western blot ana-
lysis revealed that CK2-mediated phosphorylation stabi-
lizes MZF1 protein expression (Fig. 4c, d). Consistent with
the results from Fig. 4b, luciferase reporter analysis
showed that N-cadherin promoter activity was correlated
with the MZF1 expression level (Fig. 4e). Finally, we
examined the functional effect of MZF1 expression on N-
cadherin transcription by semi-quantitative RT-PCR in
TE2 cells. We found that CK2 could upregulate N-
cadherin transcription in the presence of MZF1 wt, but
not in the presence of MZF1 S27A (Fig. 4f).
MZF1 effect on motility and invasiveness
N-cadherin-expressing cancer cells are motile, invasive,
and metastatic34,35. MKD in mesenchymally transitioned
HCE4 or TE-CK2α cells resulted in decreased motility
(Fig. 5a, b, and Supplementary Figure 2) and invasiveness
(Fig. 5c, d).
Fig. 5 Effect of MKD on motility, invasiveness, and proliferation. Effect of MKD on motility of HCE4 cells (a) or TE2-CK2α cells (b). Motility was
measured with the OrisTM Cell Migration Assay kit. *P < 0.05, **P < 0.01 compared to the C. Effect of MKD on invasion of HCE4 cells (c) or TE2-CK2α
cells (d). The cells were incubated for 48 h in the upper chambers coated with Matrigel. Data represent the mean ± SD of one experiment performed
in triplicate. Similar results were obtained from two independent experiments. *P < 0.05 compared to the C. Effect of MKD on proliferation of HCE4
cells (e) or TE2-CK2α cells (f). Cells were counted at 24 and 48 h after seeding. Data represent the mean ± SD of one experiment performed in
triplicate. Similar results were obtained from two independent experiments. C represents scrambled shRNA and M represents MZF1 shRNA,
respectively
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Discussion
EMT is a complex molecular event that regulates cell
motility, invasiveness, and metastatic tumor spread.
Expression of N-cadherin, with the concurrent loss of E-
cadherin, is a representative molecular change in the EMT
process. This study shows that CK2-mediated
MZF1 stabilization could upregulate transcription of N-
cadherin. We found that MZF1 was phosphorylated at
serine 27 by CK2, and this modiﬁcation increased the
stability of MZF1.
Our recent report showed that E-cadherin to N-
cadherin switching is achieved only by increasing CK2
activity using esophageal cancer cell lines30. We also could
demonstrate CK2-mediated E-cadherin to N-cadherin
switch in human lung cancer cells and human colon
cancer cells (data not shown). To reprogram gene
expression during the switch, CK2 may modulate tran-
scription factors responsible for E-cadherin down-
regulation and N-cadherin upregulation. The notion that
MZF1 may be involved in N-cadherin expression is hinted
by a previous report in human osteoblasts31. However,
this idea was not fully substantiated in cancer. To identify
the transcription factor for CK2-mediated N-cadherin
upregulation in cancer cells, N-cadherin promoter dele-
tion analysis was performed. In osteoblasts, two regions
(−335 to −214; −214 to −74) were reported to be
essential for N-cadherin transcription, one for the putative
Sp1 binding site (CCCCCGCCCCC −288 to −278) and
the other for the MZF1 binding site (TGGGGA located
between −150 and −145; proximal MZF1 binding site)31.
In mesenchymally transitioned cancer cells, we found a
region (−296 to −158) that showed the highest N-
cadherin promoter activity, and it contained an additional
MZF1 binding site (TCCCCA located between −277 and
−272; distal MZF1 binding site) that was not reported
previously31. Consistent with the results from our pro-
moter reporter assay, ChIP analysis showed the strong
binding of MZF1 to the distal MZF1 binding site (Fig. 1c).
When the distal MZF1 binding site was mutated
(TCCCCA to TCTTCA), the binding became reduced
even in the presence of intact proximal MZF1 binding
site, indicating that MZF1 binds mainly to the distal
MZF1 binding site in cancer cells (Fig. 1c). Over-
expression experiments showed MZF1 could increase
reporter activity with wt N-cadherin promoter but no
activity increase was observed with mutant N-cadherin
promoter that has mutations in distal MZF1 binding site.
It was concluded that, unlike osteoblast, MZF1 binds
preferentially to the distal MZF1 binding site of N-
cadherin promoter in cancer cells. Since N-cadherin
transcription was suppressed by MKD in TE2-CK2α cells,
we concluded that MZF1 is a transcription factor
responsible for CK2-mediated N-cadherin upregulation in
cancer cells (Fig. 2a, b).
How E-cadherin is downregulated during CK2-
mediated cadherin switch? The transcription factor for
E-cadherin downregulation is Snail. CK2 phosphorylates
Snail at serine 92 for stabilization36. CK2 also phosphor-
ylates β-catenin at threonine 393 for stabilization37,38.
Stabilized β-catenin then upregulates Axin2 expression,
increased Axin2 shuttles GSK3β out from the nucleus,
and thus, nuclear Snail can be no longer degraded39. We
had examined the expression of β-catenin, Snail, or Axin2
according to the CK2 activity of cancer cells. The
expressions of Snail, β-catenin, and Axin2 were higher in
cells with high CK2 activity (HCE4) than cells with low
CK2 activity (TE2 or HCE4 cells treated with TBB)
(Supplementary Figure 3).
N-cadherin-expressing cancer cells are motile, invasive,
and metastatic34,35. In agreement with previous observa-
tions, we found that cancer cells were motile as long as N-
cadherin was expressed30. Downregulation of N-cadherin
in response to MKD resulted in decreased motility (Fig.
5a, b). In addition to motility, the invasiveness of cancer
cells was dictated by the type of cadherin expressed (Fig.
5c, d)30. Our ﬁndings are consistent with reports that
migration and invasion of cancer cells depend on the
expression level of MZF140,41.
In summary, our results show that CK2 is able to
phosphorylate and stabilize MZF1, thereby upregulating
N-cadherin transcription during E-cadherin to N-
cadherin switch in cancer cells. Our results suggest that
CK2 could be a good therapeutic target that could inhibit
metastasis of cancer cells.
Materials and methods
Cell culture and reagents
The human esophageal cancer cell lines TE2, TE2-
CK2α, and HCE4, and the human embryonic kidney cell
line HEK293 were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (Gibco Laboratories, Gaithersburg,
MD, USA) supplemented with 10% fetal bovine serum
(FBS) (Gibco). The CK2 inhibitor, TBB (Sigma-Aldrich,
St. Louis, MO, USA), was prepared as a 20mM stock in
DMSO (Sigma-Aldrich).
Western blot analysis
Western blot analysis was performed as previously
described30. Blotted membranes were immunostained
with antibodies speciﬁc for the following antigens: Myc
tag (Cell Signaling Technology Inc., Beverly, MA), HA tag,
β-actin (Sigma-Aldrich), E-cadherin, and N-cadherin
(Invitrogen Co., Carlsbad, CA). Signals were developed
using Lumi-Light Western Blotting Substrate (Roche,
Indianapolis, IN, USA), according to the manufacturer’s
protocol.
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Dual-luciferase reporter assay
The indicated plasmids were transfected into the indi-
cated cell lines to examine N-cadherin or Snail promoter
activity. The pRL-TK plasmid was cotransfected in all of
the experiments to normalize luciferase activity. Forty
eight hours after transfection, cell lysates were prepared
with 200 μl Passive Lysis buffer (Promega, Madison, WI,
USA). Aliquots of 20 μl of cleared lysate were assayed for
luciferase activity with the Dual-luciferase® reporter assay
system (Promega).
GST pull down assay
Three micrograms of GST or GST-CK2α was immo-
bilized on 20 μl of Glutathione-SepharoseTM 4B resin and
incubated overnight at 4 °C with cell lysates from HEK293
cells transfected with HA-MZF1. After washing with PBS
buffer, bound proteins were eluted by heating at 100 °C
for 5 min with 2 × Laemmli sample buffer and resolved by
12% SDS-PAGE followed by western blot analysis.
Immunoprecipitation
Cells were collected and lysed in 1ml immunoprecipi-
tation lysis buffer (50 mM Tris-HCl [pH 7.4], 150mM
NaCl, 0.5% NP-40) with complete protease inhibitor
cocktail (Roche Diagnostics). The cell lysates were pre-
cleared and then incubated with the indicated antibodies
for 1 h at 4 °C. The complexes were precipitated with
Protein A/G-Sepharose beads (Santa Cruz Biotechnology
Inc.), washed, and resuspended in 40 μl SDS loading
buffer. Non-immune mouse IgG or non-immune rabbit
IgG (Santa Cruz Biotechnology Inc.) served as a negative
control.
In vitro kinase assay
To document MZF1 phosphorylation by CK2, HA-
tagged MZF1 expressed in HEK293 cells was immuno-
precipitated and used as the substrate. Immunoprecipi-
tated MZF1 and recombinant active human CK2α
(ATGen Ltd, Seongnam-si, Gyeonggi-do, Korea) were
incubated in a ﬁnal volume of 50 μl kinase reaction buffer
(10 μl of 5 × kinase buffer, 10 μl magnesium/ATP cocktail
solution [90 μl of 75 mM MgCl2/500mM ATP and 10 μl
(100 μCi) [γ-32P]-ATP]) for 20min at 30 °C. To measure
intracellular CK2 activity, an in vitro kinase assay was
performed as described previously with slight modiﬁca-
tion29. Bacterially expressed 3 μg of GST-CS (CK2 Sub-
strate; GST-RRRDDDSDDD) was incubated with
glutathione-Sepharose 4B beads for 60 min and washed
twice with kinase buffer (4 mM MOPS [pH 7.2], 5 mM β-
glycerophosphate, 1 mM EGTA, 200 μM sodium ortho-
vanadate, and 200 μM DTT). The beads were then incu-
bated with 100 μg of cell lysates in a ﬁnal volume of 50 μl
of kinase reaction buffer (10 μl of 5 × kinase buffer, 10 μl
magnesium/ATP cocktail solution [90 μl of 75 mM
MgCl2/500 mM ATP and 10 μl (100 μCi) [γ-
32P]-ATP])
for 20min at 30 °C. Reactions were stopped by washing
twice with 1 × kinase buffer. Samples were resuspended
with 30 μl of 2 × SDS sample loading buffer, subjected to
12% SDS-PAGE followed by staining with Coomassie
brilliant blue, and dried on Whatman papers. Incorpora-
tion of 32P was detected by autoradiography.
Mass spectrometry
To obtain MZF1 protein phosphorylated by CK2,
in vitro kinase assays were performed with GST-MZF1
protein and recombinant active CK2α. Reactions were
terminated by washing four times with kinase buffer.
Samples were resuspended in 40 μl 5 × SDS sample
loading buffer and boiled for 5 min. After electrophoresis,
SDS polyacrylamide gels were stained with G250 Coo-
massie blue. GST-MZF1 was excised and digested in-gel
with sequencing-grade, modiﬁed trypsin (Promega). In
brief, the GST-MZF1 spot was excised from the gel,
placed in a polypropylene tube, and washed four to ﬁve
times with 150 μl of 1:1 acetonitrile/25 mM ammonium
bicarbonate, pH 7.8. The gel slice was dried in a Speedvac
concentrator and then rehydrated in 30 μl of 25 mM
ammonium bicarbonate, pH 7.8, containing 20 ng of
trypsin. After incubation at 37 °C for 20 h, the liquid was
transferred to a new tube. Tryptic peptides remaining in
the gel matrix were extracted for 40 min at 30 °C with 20
μl of 50% (v/v) aqueous acetonitrile containing 0.1% (v/v)
formic acid. The combined supernatants were evaporated
in a Speedvac concentrator and dissolved in 8 μl of 5% (v/
v) aqueous acetonitrile solution containing 0.1% (v/v)
formic acid for mass spectrometric analysis. The resulting
tryptic peptides were separated and analyzed by reverse-
phase capillary HPLC directly coupled to a Finnigan LCQ
ion-trap mass spectrometer (LC-MS/MS). A 0.1 × 20-mm
trapping column and a 0.075 × 130-mm resolving column
were packed with Vydac 218 MS low triﬂuoroacetic acid
C18 beads (5 μm in size, 300 Å in pore size; Vydac,
Hesperia, CA) and placed in-line. The peptides were
bound to the trapping column for 10min with 5% (v/v)
aqueous acetonitrile containing 0.1% (v/v) formic acid.
The bound peptides were then eluted with a 50-min
gradient of 5–80% (v/v) acetonitrile containing 0.1% (v/v)
formic acid at a 0.2 μl/min ﬂow rate. The full mass scan
range mode was m/z= 450–2000 Da for tandem mass
spectrometry. After the charge state of an ion was
determined on the zoom scan, product ion spectra were
acquired in MS/MS mode with relative collision energy of
55%. The individual spectra from MS/MS were processed
with TurboSEQUEST software (Thermo Quest, San Jose,
CA). The generated peak list ﬁles were used to query
either the MSDB database or NCBI with the MASCOT
program (http://www.matrixscience.com). Modiﬁcations
of methionine and cysteine, peptide mass tolerance at
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2 Da, MS/MS ion mass tolerance at 0.8 Da, allowance of
missed cleavage at 2, and charge states (+1,+2, and +3)
were all considered. Only signiﬁcant hits by MASCOT
probability analysis were initially considered.
Site-directed mutagenesis of MZF1 and MZF1 binding site
on N-cadherin promoter
Site-directed mutagenesis of MZF1 or of the MZF1-
binding site in the N-cadherin promoter was performed
with a QuikChange site-directed mutagenesis kit (Strata-
gene). All mutant constructs were conﬁrmed by DNA
sequencing. The following mutagenic primer pairs were
used to generate mutants: MZF1S27A: forward, 5′-
TAGAGGACGCTGAGGAGGAG-3′; reverse, 5′-
CTCCTCCTCAGCGTCCTCTA-3′. MZF1S27E: forward,
5′-TAGAGGACGAGGAGGAGGAG-3′; reverse, 5′-
CTCCTCCTCCTCGTCCTCTA-3′. For mutations in the
distal MZF1-binding site (TCCCCA to TCTTCA) in
pNcad-667 (pNcad-667mt): forward, 5′-
TTCCCCCGCCCCCTCTTCAGCTCCTTGATC-3′;
reverse, 5′-GATCAAGGAGCTGAA-
GAGGGGGCGGGGGAA-3′.
Chromatin immunoprecipitation (ChIP) assay
The in vivo molecular interaction between MZF1 and
the N-cadherin promoter was analyzed by ChIP assay.
HCE4 cells were transfected with pSG5-HA or pSG5-HA-
MZF1 using Lipofectamine Plus (Invitrogen Co.). For the
ChIP assay, chromatin was ﬁrst isolated as follows.
Approximately 2 × 109 cells were treated with PBS con-
taining 1% formaldehyde for 10min, washed twice with
PBS, and then incubated with 100 mM Tris (pH 9.4) and
10mM DTT at 30 °C for 15min. Cells were then washed
twice with PBS and resuspended in 600 μl of Sol A buffer
(10 mM HEPES [pH 7.9], 0.5% NP-40, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM DTT) by pipetting. After a short spin
(5 min at 3,000 rpm), the pellets were resuspended in Sol
B buffer (20 mM HEPES [pH 7.9], 25% glycerol, 0.5% NP-
40, 0.42M NaCl, 1.5 mM MgCl2, and 0.2 mM EDTA)
containing protease inhibitors followed by vigorous
pipetting in order to extract the nuclear proteins. After
centrifugation at 13,000 rpm for 30 min, the nuclear pel-
lets were resuspended in immunoprecipitation buffer (1%
Triton X-100, 2 mM EDTA, 20mM Tris-HCl [pH 8.0],
150mM NaCl, and protease inhibitors) and sonicated to
break the chromatin into fragments with an average
length of 0.5–1 kb. ChIP analysis of MZF1 binding to the
N-cadherin promoter was performed with an antibody
against HA or a nonspeciﬁc IgG Primers used were for-
ward, 5′-GCTGCATCCCTCGCGGCTTC-3′, and
reverse, 5′-GACAAATAGCGGGCCGCGGA-3′. To
conﬁrm MZF1 binding to a distal MZF1-binding site,
HCE4 cells were transfected with pNcad-667 or pNcad-
667mt with pSG5-HA or pSG5-HA-MZF1. Primers used
were forward: sequences in pGL3-basic; reverse, 5′-
CGAAGAGCCGGAGGAGGCGG-3′.
Generation of stable MKD cells
shRNA-mediated knockdown of MZF1 was performed
using the HuSH-plasmid system (Origene Technologies
Inc., Rockville, MD, USA). The shRNA sequences tested
were as follows: Sequence #1: CCTGTCATGGT-
GAAGCTAGAGGACTCTGA. Sequence #2:
TGCGATGTATGTGGCAAGGTGTTCAGCCA.
Sequence #3: AGCATCTCCGCAGGTCCAGGTAGTG-
TAAG. Sequence #4: GGTTACAGAGGACTCA-
GATTTCCTGGAGT. We validated all constructs
individually and found the #4 was the most effective
construct for MKD (Supplementary Figure 1). After that,
we used #4 construct for MKD. HCE4 cells were trans-
fected with pRS-shMZF1#4 followed by treatment with
puromycin (2 μg/ml) for selection, and TE2-CK2α cells
were transfected with pGFP-B-RS-shMZF1#4 (Origene
Technologies Inc.) followed by treatment with puromycin
(1 μg/ml) and blasticidin (6 μg/ml) for selection.
RNA isolation and reverse-transcription PCR (RT-PCR)
RNA was isolated from cultured cells with TRIzol
(Invitrogen Co.) reagent. cDNA was synthesized with
SuperScript II reverse transcriptase (Invitrogen Co.) and
oligo-dT primers. PCR reactions were performed with 2 μl
cDNA and a pair of primers speciﬁc for each gene. The
sequences of the RT-PCR primers were: N-cadherin:
forward, 5′-CACCCAACATGTTTACAATCAA-
CAATGAGA-3′; reverse, 5′-CTGCAGCAA-
CAGTAAGGACAAACATCCTAT-3′. MZF1: forward,
5′-CGCAGGTCCAGGTAGTGTAA-3′; reverse, 5′-
ACTCTCCGATGCTCTTCCAG-3′.
Quantitative real-time (qRT) PCR analysis
qRT-PCR was performed using Power SYBR Green PCR
Master Mix (Applied Biosystems, Carlsbad, CA, USA). All
qRT-PCR performed using SYBR Green was conducted at
50 °C for 2 min, 95 °C for 10min, and then 40 cycles of
95 °C for 15 s and 60 °C for 1 min. The speciﬁcity of the
reaction was veriﬁed by melt curve analysis.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as a normalization control. The sequences of the
qRT-PCR primers were: MZF1 forward, 5′-
GGGCCTGCAGGTGAAAGAG-3′; reverse, 5′-
GGCAGCTAGAGGCCCAGACT-3′, GAPDH forward,
5′-GGCATCCTGGGCTACACTGA-3′; reverse, 5′-
GAGTGGGTGTCGCTGTTGAA-3′.
Cell proliferation assay
Cells were counted at 24 and 48 h after seeding, using
an ADAM automatic Cell Counter (NanoEnTek, Inc.,
Seoul, Korea). Data represent the mean ± SD of one
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experiment performed in triplicate. Similar results were
obtained from two independent experiments.
Cell migration and invasion assay
The cell migration assay was performed with the
OrisTM Cell Migration Assay kit (Platypus Technologies,
LLC, Madison, WI, USA). Migration was quantiﬁed by
measuring the cell surface area with ImageJ. Invasion was
determined using 24-well chemotaxis chambers (Corning
cell culture inserts, 8 μm pore size) with membranes pre-
coated with Matrigel Basement Membrane Matrix (BD
Biosciences, CA, USA). Complete medium with 10% FBS
served as a chemoattractant in the bottom chamber and
4 × 105 cells per ml cells were incubated for 48 h. Invaded
cells at the bottom surface of the membrane were stained
with 1% sulforhodamine B (SRB) for 5 min, dried and
photographed. Bound dye was eluted with 10mM Tris-
HCl (pH 7.0). The ability of cell invasion was reﬂected by
measuring the absorbance at 510 nm in a microplate
reader.
Statistical analysis
Statistical comparisons of groups were made using a
Student’s t test, and P < 0.05 was considered signiﬁcant.
The Pearson correlation test was performed using R 3.0.
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